Seaport Therapeutics, Inc. (NASDAQ: SPTX) has set terms for its initial public offering, marketing 11.8 million shares at a price range of $16 to $18, implying a deal size of approximately $200 million at the midpoint and an estimated post-offer market capitalization of roughly $860 million. The offering is being led by Goldman Sachs, J.P. Morgan, Leerink Partners, Citigroup, and Stifel, with shares expected to list on the Nasdaq Global Market.
Seaport is a clinical-stage therapeutics company focused on developing novel oral treatments for depression, anxiety, and other neuropsychiatric disorders. The company’s strategy centers on its proprietary Glyph™ platform, a lymphatic-targeting prodrug technology designed to bypass first-pass liver metabolism, improve oral bioavailability, and reduce side effects—key limitations that have historically constrained otherwise clinically validated drug mechanisms.
The lead program, GlyphAllo (SPT-300), is an oral prodrug of allopregnanolone, a neurosteroid with established antidepressant activity. While prior formulations have demonstrated rapid efficacy in postpartum depression, their broader use has been limited by delivery challenges. Seaport’s approach aims to replicate these benefits through a convenient oral therapy, with early clinical data demonstrating therapeutic exposure levels and favorable tolerability. The program is currently advancing through a Phase 2b registration-enabling trial in major depressive disorder, with topline data expected in the first half of 2027.
A second key asset, GlyphAgo (SPT-320), targets generalized anxiety disorder and major depressive disorder as an oral prodrug of agomelatine, a clinically validated antidepressant and anxiolytic approved outside the U.S. Early data from a Phase 1 trial showed significantly improved bioavailability and reduced variability compared to unmodified agomelatine, supporting further clinical development. The company plans to initiate Phase 2 trials with multiple data readouts expected through 2028.
Seaport is also advancing Glyph2BLSD (SPT-348), a non-hallucinogenic LSD analog designed to address treatment-resistant depression, PTSD, and other CNS disorders. Still in preclinical development, the program reflects the broader potential of the Glyph platform to unlock new therapeutic applications across neuropsychiatry and beyond.
The company’s pipeline is supported by a team with deep experience in neuropsychiatric drug development, including leadership involved in therapies such as Zyprexa, Cymbalta, Latuda, and more recently Cobenfy, a first-in-class schizophrenia treatment. Seaport’s founders were also instrumental in the development of Karuna Therapeutics, which was acquired by Bristol Myers Squibb in 2024 for $14 billion, highlighting a track record of translating early-stage innovation into meaningful outcomes.
Financially, Seaport reflects a typical early-stage biotech profile with no revenue and increasing investment in clinical development. The company reported a net loss of approximately $74.9 million in 2025, compared to $46.9 million in 2024, driven primarily by rising research and development expenses as pipeline programs advance.
Proceeds from the offering are expected to fund continued development of GlyphAllo, GlyphAgo, and Glyph2BLSD, along with advancing additional programs and supporting general corporate purposes.
From a positioning standpoint, Seaport enters the public markets as part of a continued wave of biotech IPOs focused on differentiated platforms targeting large, underserved therapeutic areas. While the Glyph platform offers a compelling approach to improving known drug mechanisms, the investment case remains tied to clinical execution, regulatory progress, and the ability to translate early pharmacokinetic advantages into durable patient outcomes—key risks typical of pre-commercial CNS-focused biotech companies.
Seaport is expected to price Thursday, April 30th and begin trading Friday, May 1st on the Nasdaq under the ticker SPTX.